Natixis Advisors LLC Acquires 3,193 Shares of Haemonetics Co. (NYSE:HAE)

Natixis Advisors LLC boosted its stake in Haemonetics Co. (NYSE:HAE) by 28.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,324 shares of the medical instruments supplier’s stock after purchasing an additional 3,193 shares during the quarter. Natixis Advisors LLC’s holdings in Haemonetics were worth $1,185,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently made changes to their positions in the business. TFO Wealth Partners LLC grew its stake in shares of Haemonetics by 29,450.0% in the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 589 shares during the last quarter. Covestor Ltd increased its stake in Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 438 shares in the last quarter. EntryPoint Capital LLC purchased a new position in shares of Haemonetics in the first quarter worth $86,000. Headlands Technologies LLC purchased a new position in shares of Haemonetics during the first quarter valued at approximately $114,000. Finally, Central Pacific Bank Trust Division bought a new position in Haemonetics in the first quarter valued at about $139,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

HAE has been the topic of several recent research reports. Needham & Company LLC raised Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective on the stock in a research note on Wednesday, June 12th. JMP Securities restated a “market outperform” rating and issued a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. Barrington Research increased their target price on shares of Haemonetics from $107.00 to $108.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. BTIG Research assumed coverage on shares of Haemonetics in a research note on Tuesday. They set a “buy” rating and a $112.00 price target for the company. Finally, Citigroup dropped their price objective on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $108.40.

Insider Buying and Selling

In related news, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total transaction of $192,240.00. Following the sale, the executive vice president now directly owns 21,410 shares of the company’s stock, valued at $1,926,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total transaction of $192,240.00. Following the completion of the transaction, the executive vice president now owns 21,410 shares of the company’s stock, valued at $1,926,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Stewart W. Strong sold 4,312 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the sale, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The disclosure for this sale can be found here. 1.80% of the stock is currently owned by corporate insiders.

Haemonetics Price Performance

HAE opened at $73.94 on Wednesday. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97. The business’s 50-day moving average is $82.01 and its two-hundred day moving average is $84.03. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33. The firm has a market capitalization of $3.78 billion, a PE ratio of 32.29, a price-to-earnings-growth ratio of 1.33 and a beta of 0.30.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The firm had revenue of $336.17 million during the quarter, compared to analysts’ expectations of $335.08 million. During the same quarter in the previous year, the business earned $1.05 earnings per share. The company’s revenue for the quarter was up 8.0% compared to the same quarter last year. Research analysts anticipate that Haemonetics Co. will post 4.58 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.